Cytrx Corporation

Richter Gedeon Vegyeszeti Gyar Rt

Omeros Corporation

Biorex Kutato Es Fejleszto Rt

Biorex Research & Development Co.

Biorex Kutato Es Fejleszo Rt.

László Ürögdi

Ede Márványos

Magdolna Bathóné Török

Zita Jegesné Csákai

László Dénes

Laszlo Szporny

Eva Palosi

Lajos Kisfaludy

Andrea Jednakovits

Mihaly Barabas

Jennifer Lynn Gage

Neil S Cutshall

Szabolcs Szeberenyi

Gábor Balogh

Laszlo Jaszlits

Ibolya Horváth

Katalin Biro

John E Bergmann

Hongkui Zeng

Péter Literáti Nagy

László Vígh

Zsolt Török

Mária Kürthy

Rene Onrust

Sándor Cseh

Andrea Jednákovits

László Korányi

Katalin Bíró

György Dormán

Attila Glatz

Beatrix Farkas

Derek Johnston

Ákos Papp

Bea Mézes

László Jaszlits

Mihály Barabás

Erzsébet Hegedüs

Éva Udvardy

Dénes Medzihradszky

Eszter Kovács

Adam Sarkadi

Laszlo Vereczkey

Laszlo Tvos

Gyorgy Dorman

Helga Tudos Nee Feuer

Erzsebet Radvanyi Nee Hegedus

Julia Rohricht

Jenö Szilbereky

Erzsebet Radvanyne

Istvanne Udvardy Nagy

Istvanne Udvardy-Nagy

Julianna Rohricht

Agnes Patthy Nee Lukats

Erno Moravcsik

Zsuzsanna Tegyei

Anió Szakácsné-Schmidt

Ernö Duda

Jenó Szilbereky

Ernó Duda

Zita Jegesné-Csákai

Lajos Gruber

László Ötvös

József Tóth

István Tömösközi

Magdolna Torok

Ferencné Reider

Mária Schneiderné-Barlay

Sandor Erdo

Erno Bacsy

Marta Vitai

Gyorgy Schmidt

Marta Sinka

Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. The compounds have the general structure: wherein m, n, p, x, R, R, R, R, R, R, A and B, are defined herein, including pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same.

PDE10 inhibitors and related compositions and methods

A method of increasing expression of a molecular chaperon by a cell and/or enhancing the activity of a molecular chaperon in cells is provided. The method comprises treating a cell that is exposed to a physiological stress which induces expression of a molecular chaperon by the cell with an effective amount of a certain hydroxylamine derivative to increase the stress. Alternatively, an hydroxylamine derivative can be administrated to a cell before it is exposed to a physiological stress which induces expression of a molecular chaperon by the cell. Preferably, the cell to which an hydroxylamine derivative is administered is an eukaryotic cell. The hydroxylamine derivative corresponds to the formulae (I) or (II). The invention also provides novel hydroxylamine derivatives falling within the scope of the formulae (I) and (II) as well as pharmaceutical and/or cosmetical compositions comprising the said compounds.

Method of enhancing cellular production of molecular chaperone, hydroxylamine derivatives useful for enhancing the chaperone production and the preparation thereof

The subject invention relates to carboxamidine derivatives, to pharmaceutical compositions comprising the same, and the use thereof in the preparation of pharmaceutical compositions for the treatment of vascular diseases.

Carboxamidine derivatives and their use in the treatment of vascular diseases

The subject invention relates to carboxamidine derivatives, to pharmaceutical compositions containing the carboxamidine derivatives of the invention, and the use thereof for the treatment of vascular diseases and in the preparation of pharmaceutical compositions for the treatment of vascular diseases.

Pharmaceutically effective compounds

The invention relates to carboxamidine derivatives to pharmaceutical compositions containing the same and the use thereof in the preparation of pharmaceutical compositions for the treatment of vascular diseases.

Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof

The invention relates to N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboxamidine and its optically active enantiomers. (R)-(&#x2212;)-N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboxamidine and (S)-(+)-N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboxamidine. Furthermore, the invention relates to the preparation of N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboxyimidoyl chloride, which may be used as an active ingredient of medicaments, and the preparation of the optically active enantiomers of this compound using the compounds of the invention as intermediate substances.

Pyridine-1-oxide derivative, and process for its transformation into pharmaceutically effective compounds

Pharmaceutical products for curing and preventing illnesses connected

Anti-ischaemic hydroxylamine derivatives and pharmaceutical compositions

Hydroximic acid derivatives, pharmaceutical compositions containing

The invention relates to new tetrahydro-1,2,4-oxadiazin-5-one derivatives having a CNS activity. More particularly, the invention concerns new N.sup.4 -substituted tetrahydro-1,2,4-oxadiazin-5-ones of the formula (1) ##STR1## wherein R.sup.2 is benzyloxycarbonyl or alkylcarbonyl containing 1 to 4 carbon atoms in the alkyl moiety, preferably acetyl;

N4-Substituted tetrahydro-1,2,4-oxadiazin-5-one derivatives having

An N-substituted carbonyl tetrahydrobenzodiazepines having ethoxycarbonyl, formyl, carbamoyl or methyl carbamoyl as the N.sup.4 substituent.

1,3,4,5-Tetrahydro-2H-1,4-benzodiazepin-2-ones

New benzodiazepine derivatives of the formula (I), ##STR1## wherein R.sub.1 stands for halogen, trifluoromethyl, nitro or amino,

Benzodiazepine derivatives

Growing community of inventors

Budapest, Hungary

László Ürögdi